United States · Who invested in Tolero Pharmaceuticals?
Tolero Pharmaceuticals's investors include Fred Alger Management.
20132014
$3.3MVenture$22MSeries BUnited States · Series B startup
Who invested in Tolero Pharmaceuticals
2 rounds we have observed, with the one investor named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$26Mraised across 2 rounds since 2012, from 2 sources
$3.3MVenture$22MSeries B
- Latest round
- Series B, $22MNov 2014
- Step-upi
- 6.7×
- Investors
- 1
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Venture, $3.3M Jul 2012
- Biggest round
- $22M Series B · Nov 2014
- Between rounds
- 2.3 years from the last two
The rounds
- Nov 2014Series B$22M1 new
From a historical funding recordSEC filing: $22M sold, first sale Aug 2014
- Jul 2012Venture$3.3M
No investor was named in the report.
Reported by sec.govSEC filing: $3.3M sold, first sale Jul 2012
Quick answers about Tolero Pharmaceuticals
How much has Tolero Pharmaceuticals raised?
Tolero Pharmaceuticals has raised $26M across 2 rounds since 2012.
When did Tolero Pharmaceuticals last raise?
Tolero Pharmaceuticals's most recent round was a Series B of $22M in Nov 2014.
What was Tolero Pharmaceuticals's biggest round?
Its most recent round, $22M in Nov 2014, is also its largest on record.
Who backed Tolero Pharmaceuticals first?
Tolero Pharmaceuticals's first round on record, in Nov 2014, was backed by Fred Alger Management.
What stage is Tolero Pharmaceuticals at?
Tolero Pharmaceuticals's latest named round is a Series B, in Nov 2014.
Where is Tolero Pharmaceuticals based?
Tolero Pharmaceuticals is based in the United States.
Companies like Tolero Pharmaceuticals
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.